CIGB-300 synthetic peptide, an antagonist of CK2 kinase activity, as a treatment for Covid-19. A computational biology approach
Preprint
Abstract
Drug repositioning became the first choice for treating Covid-19 patients due to the urgent need to deal with the pandemic. Similarities in the hijacking mechanisms used by SARS-CoV-2 and several type of cancer, suggest the repurposing of cancer drugs to treat Covid-19. CK2 kinase antagonists have been proposed for the treatment of cancer. A recent study in cells infected with SARS-CoV-2 virus found a significant CK2 kinase activity, and the use of a CK2 inhibitor showed antiviral responses. CIGB-300, originally designed as an anticancer peptide, is an antagonist of CK2 kinase activity that binds to CK2 phospho-acceptor sites. Recent preliminary results show an antiviral activity of CIGB-300 versus a surrogate model of coronavirus. Here we present a computational biology study that provides evidences at the molecular level of how CIGB-300 might interfere with SARS-CoV-2 life cycle inside infected human cells. First, from SARS-CoV studies, we infer the potential incidence of CIGB-300 in SARS-CoV-2 interference on immune response. Next, from the analysis of multiple Omics data, we propose the action of CIGB-300 since early stage of viral infections perturbing the virus hijacking of RNA splicing machinery. It was also predicted the interference of CIGB-300 in virus-host interactions responsible for the high infectivity and the particular immune response to SARS-CoV-2 infection. Further, we provide evidences of CIGB-300 attenuation of phenotypes related to muscle, bleeding, coagulation and respiratory disorders.Keywords
All Related Versions
This publication has 77 references indexed in Scilit:
- Artificial intelligence in COVID-19 drug repurposingThe Lancet Digital Health, 2020
- The Global Phosphorylation Landscape of SARS-CoV-2 InfectionCell, 2020
- Drug repositioning is an alternative for the treatment of coronavirus COVID-19International Journal of Antimicrobial Agents, 2020
- CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteomeMolecular and Cellular Biochemistry, 2020
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19Cell, 2020
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposingNature, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Implication of B23/NPM1 in Viral Infections, Potential Uses of B23/NPM1 Inhibitors as Antiviral TherapyInfectious Disorders - Drug Targets, 2019
- Biophysical Characterization of Nucleophosmin Interactions with Human Immunodeficiency Virus Rev and Herpes Simplex Virus US11PLOS ONE, 2015
- Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activityMolecular Cancer Therapeutics, 2009